TTLL4

Across TCGA pan-cancer cohorts, TTLL4 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated TTLL4 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TTLL4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TTLL4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

BLCA, UVM, and UCEC are the cancer types where TTLL4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	IV	0.089	0.484	<.001	24	view →
UVM	DFS	Median	All	0.079	0.746	<.001	18	view →
UCEC	DFS	Median	All	0.905	0.619	.038	8	view →
UCS	DFS	Median	All	0.126	0.523	.009	6	view →
SCLC	OS	Median	All	0.082	0.822	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	All	0.785	0.393	.019	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
SKCM	OS	Median	III,IV	0.632	0.822	.019	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

TTLL4–BLCA (DFS)

Open the BLCA breakdown →